VORANIGO
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- VORANIGO
- Generic name
- VORASIDENIB
- Manufacturer
- Servier Pharmaceuticals LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 31405fee-55b7-4857-987e-2724ee76be84
- SPL ID
- ee016d13-6ef7-4e50-bb23-d8ece41d549d
- Version
- 9
- Effective date
- 2026-06-20
- Source export date
- 2026-11-13
- Source partition
- 8
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/5b373538593b900129b6789b4289137dca62e689b6d06cab0e8e33844e7e2588/drug-label-0008-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:55:17
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 218784 | derived:openfda.application_number |
| application number | NDA218784 | openfda.application_number | |
| brand name | VORANIGO | openfda.brand_name | |
| generic name | VORASIDENIB | openfda.generic_name | |
| manufacturer name | Servier Pharmaceuticals LLC | openfda.manufacturer_name | |
| ndc | package | 72694-879-10 | openfda.package_ndc |
| ndc | package | 72694-728-40 | openfda.package_ndc |
| ndc | product | 72694-728 | openfda.product_ndc |
| ndc | product | 72694-879 | openfda.product_ndc |
| ndc11 | package | 72694072840 | derived:openfda.package_ndc |
| ndc11 | package | 72694087910 | derived:openfda.package_ndc |
| rxcui | 2690661 | openfda.rxcui | |
| rxcui | 2690653 | openfda.rxcui | |
| rxcui | 2690659 | openfda.rxcui | |
| rxcui | 2690663 | openfda.rxcui | |
| spl id | ee016d13-6ef7-4e50-bb23-d8ece41d549d | id | |
| spl set id | 31405fee-55b7-4857-987e-2724ee76be84 | set_id | |
| unii | 789Q85GA8P | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hepatotoxicity : VORANIGO can cause hepatic transaminase elevations, which can lead to hepatic failure, hepatic necrosis, and autoimmune hepatitis. Monitor liver function tests every 2 weeks during the first 2 months of treatment, then monthly for the first 2 years of treatment, and as clinically indicated. Withhold, reduce the dose or discontinue VORANIGO based on severity. ( 2.3 , 5.1 ) Embryo-Fetal Toxicity : VORANIGO can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective nonhormonal contraception. ( 5.2 , 8.1 , 8.3 ) 5.1 Hepatotoxicity VORANIGO can cause hepatic transaminase elevations, which can lead to hepatic failure, hepatic necrosis, and autoimmune hepatitis. In the pooled safety population [see Adverse Reactions (6.1) ] , 58% of patients treated with VORANIGO experienced increased ALT and 44% of patients experienced increased AST. Grade 3 or 4 increased ALT or AST occurred in 9% and 4.8% of patients respectively. Among these patients, 4.1% (10/244) had concurrent Grade 3 to 4 ALT or AST elevations. A total of 34% of patients treated with VORANIGO had increased gamma-glutamyl transferase (GGT), of these 2.2% were Grade 3 or 4. Bilirubin increases occurred in 4.8% of patients treated with VORANIGO, with 0.4% Grade 3 or 4. Nine percent of patients treated with VORANIGO had increased alkaline phosphatase, with 0.9% Grade 3 or 4. Two patients met the laboratory criteria for Hy's Law and had concurrent elevations in ALT or AST >3 times the upper limit of normal and total bilirubin >2 times the upper limit of normal; these events were associated with cases of autoimmune hepatitis and hepatic failure. The median time to first onset of increased ALT or AST was 57 days (range: 1 to 1049). Acute hepatitis occurred in the postmarketing setting. Permanent discontinuation of VORANIGO was required for 2.9% of patients with ALT elevations, 1.6% of AST elevations, and 0.4% of GGT elevations. Dosage reductions of VORANIGO were required for 7% of patients with ALT elevations, 1.2% of AST elevations, and 0.4% of GGT elevations. Dosage interruptions were required in 14% of patients with ALT elevations, 6% of AST elevations, and 1.6% of GGT elevations. Monitor liver laboratory tests (AST, ALT, GGT, total bilirubin and alkaline phosphatase) prior to the start of VORANIGO, every 2 weeks during the first 2 months of treatment, then monthly for the first 2 years of treatment, and as clinically indicated, with more frequent testing in patients who develop transaminase elevations. Reduce the dose, withhold, or permanently discontinue VORANIGO based on severity [see Dosage and Administration (2.3) and Adverse Reactions (6.1) ]. 5.2 Embryo-Fetal Toxicity Based on findings from animal studies, VORANIGO can cause fetal harm when administered to a pregnant woman. In animal embryo-fetal development studies, oral administration of vorasidenib to pregnant rats during the period of organogenesis caused embryo-fetal toxicities at doses ≥45 times the human exposure based on the area under the concentration-time curve (AUC) at the highest recommended dose. Oral administration of vorasidenib to pregnant rabbits during the period of organogenesis resulted in embryo-fetal toxicity at doses ≥8 times the human exposure based on the AUC at the highest recommended dose. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective nonhormonal contraception during treatment with VORANIGO and for 3 months after the last dose, since VORANIGO can render some hormonal contraceptives ineffective [see Drug Interactions (7.2) ] . Advise male patients with female partners of reproductive potential to use effective contraception during treatment with VORANIGO and for 3 months after the last dose [see Use in Specific Populations (8.1 , 8.3) ] .
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Hepatotoxicity [see Warnings and Precautions (5.1) ] The most common (≥15%) adverse reactions include fatigue, headache, COVID-19, musculoskeletal pain, diarrhea, nausea, and seizure. Grade 3 or 4 (≥2%) laboratory abnormalities were ALT increased, AST increased, GGT increased, and neutrophils decreased. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Servier Pharmaceuticals at 1-800-807-6124 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions described in the WARNINGS AND PRECAUTIONS reflect exposure to VORANIGO 40 mg orally once daily until disease progression or unacceptable toxicity in the 244 patients with astrocytoma or oligodendroglioma with susceptible IDH1 or IDH2 mutation in trials AG881-C-002 (NCT02481154, n=11), AG120-881-001 (NCT03343197, n=14) and INDIGO (NCT04164901, n=167 randomized patients and n=52 crossover patients). Among the 244 patients who received VORANIGO, 78% were exposed for 6 months or longer and 44% were exposed for greater than one year. In this pooled safety population, the most common (≥15%) adverse reactions were fatigue (33%), headache (28%), COVID-19 (28%), musculoskeletal pain (24%), diarrhea (21%), nausea (20%), and seizure (16%). In this pooled safety population, the most common (≥2%) Grade 3 or 4 laboratory abnormalities were increased ALT (9%), increased AST (4.8%), increased GGT (2.2%), and decreased neutrophils (2.2%). INDIGO The safety of VORANIGO was evaluated in 330 patients with Grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation who received at least one dose of either VORANIGO 40 mg daily (N=167) or placebo (N=163) in the INDIGO trial [see Clinical Studies (14) ] . Patients received VORANIGO 40 mg orally once daily or placebo orally once daily until disease progression or unacceptable toxicity. Among the 167 patients who were randomized and received VORANIGO, the median duration of exposure to VORANIGO was 12.7 months (range: 1 to 30 months) with 153 patients (92%) exposed to VORANIGO for at least 6 months and 89 (53%) exposed for at least 1 year. The demographics of patients randomized to VORANIGO were: median age 41 years (range: 21 to 71 years); 60% male, 74% White, 20% race not reported, 3% Asian, and 1.2% Black or African American; and 5% were Hispanic or Latino. Serious adverse reactions occurred in 7% of patients who received VORANIGO. The most common serious adverse reactions occurring in ≥2% of patients who received VORANIGO includes seizure (3%). Permanent discontinuation of VORANIGO due to an adverse reaction occurred in 3.6% of patients. Adverse reactions which resulted in permanent discontinuation of VORANIGO in ≥2% of patients included ALT increased (3%). Dosage interruptions of VORANIGO due to an adverse reaction occurred in 30% of patients. Adverse reactions which required dose interruption in ≥5% of patients included ALT increased (14%), COVID-19 (9%), and AST increased (6%). Dose reductions of VORANIGO due to an adverse reaction occurred in 11% of patients. Adverse reactions which required dose reduction in ≥5% of patients included ALT increased (8%). The most common (≥15%) adverse reactions were fatigue (37%), COVID-19 (33%), musculoskeletal pain (26%), diarrhea (25%), and seizure (16%). Grade 3 or 4 (≥2%) laboratory abnormalities were ALT increased (10%), AST increased (4.8%), GGT increased (3%) and neutrophil decreased (2.4%). Adverse reactions and select laboratory abnormalities reported in the INDIGO trial are shown in Tables 3 and 4. Table 3: Adverse Reactions (≥5%) in Patients with Grade 2 IDH1/2 Mutant Glioma Who Received VORANIGO Compared with Placebo in the INDIGO Trial VORANIGO 40 mg daily (n=167) Placebo (n=163) Adverse Reaction Adverse reactions are based on NCI CTCAE v5.0. All Grades (%) Grades 3 or 4 (%) All Grades (%) Grades 3 or 4 (%) General Disorders Fatigue Grouped term includes asthenia. 37 0.6 36 1.2 Infections and Infestations COVID-19 33 0 29 0 Nervous System Disorders Seizure Grouped term includes partial seizures, generalized tonic-clonic seizure, epilepsy, clonic convulsion, and simple partial seizures. 16 4.2 15 3.7 Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain Grouped term includes arthralgia, back pain, non-cardiac chest pain, pain in extremity, myalgia, neck pain, musculoskeletal chest pain, arthritis, and musculoskeletal stiffness. 26 0 25 1.8 Gastrointestinal Disorders Diarrhea Grouped term includes feces soft and frequent bowel movements. 25 0.6 17 0.6 Constipation 13 0 12 0 Abdominal pain Grouped term includes abdominal pain upper, abdominal discomfort, abdominal pain lower, abdominal tenderness, and epigastric discomfort. 13 0 12 0 Decreased appetite 9 0 3.7 0 Table 4: Select Laboratory Abnormalities (≥5%) That Worsened from Baseline in Patients with Grade 2 IDH1/2 Mutant Glioma Who Received VORANIGO in the INDIGO Trial VORANIGO 40 mg daily N=167 Placebo N=163 Parameter All Grades Based on NCI CTCAE v5.0. (% The denominator used to calculate percentages is N, the number of subjects in the Safety Analysis Set within each treatment group. ) Grades 3 or 4 (% ) All Grades (% ) Grades 3 or 4 (% ) Abbreviations: AST = Aspartate Aminotransferase; ALT = Alanine Aminotransferase; GGT = Gamma-Glutamyl Transferase; ALP = Alkaline Phosphatase Chemistry Increased ALT 59 10 25 0 Increased AST 46 4.8 20 0 Increased Creatinine 11 0.6 7 0 Decreased Calcium 10 0 7 0 Increased Glucose Includes adverse reaction term hyperglycemia. 10 0 4.3 0 Increased GGT 38 3 10 1.8 Decreased Phosphate Includes adverse reaction terms hypophosphatemia and blood phosphorus decreased. 8 0.6 4.9 0 Increased Potassium 23 0.6 20 0 Increased ALP 10 1.2 7 0.6 Hematology Increased Hemoglobin 13 0 3.1 0 Decreased Lymphocytes 11 1.8 8 0.6 Decreased Leukocytes 13 0.6 12 0.6 Decreased Neutrophils 14 2.4 12 1.8 Decreased Platelets 12 0 4.3 0
adverse reactions table
<table width="80%"> <caption>Table 3: Adverse Reactions (≥5%) in Patients with Grade 2 IDH1/2 Mutant Glioma Who Received VORANIGO Compared with Placebo in the INDIGO Trial</caption> <colgroup> <col width="40%" align="left" valign="bottom"/> <col width="15%" align="center" valign="bottom"/> <col width="15%" align="center" valign="bottom"/> <col width="15%" align="center" valign="bottom"/> <col width="15%" align="center" valign="bottom"/> </colgroup> <thead> <tr styleCode="Botrule First"> <th styleCode="Lrule Rrule" align="left"/> <th styleCode="Rrule" colspan="2" align="center" valign="middle">VORANIGO 40 mg daily (n=167)</th> <th styleCode="Rrule" colspan="2" align="center" valign="middle">Placebo (n=163)</th> </tr> <tr> <th styleCode="Lrule Rrule" align="left">Adverse Reaction<footnote ID="L31441867-50cf-45b5-a542-7234febe1ea6">Adverse reactions are based on NCI CTCAE v5.0.</footnote> </th> <th styleCode="Rrule" align="center">All Grades (%)</th> <th styleCode="Rrule" align="center">Grades 3 or 4 (%)</th> <th styleCode="Rrule" align="center">All Grades (%)</th> <th styleCode="Rrule" align="center">Grades 3 or 4 (%)</th> </tr> </thead> <tbody> <tr styleCode="Botrule First"> <td styleCode="Lrule Rrule" colspan="5" align="left"> <content styleCode="bold">General Disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Fatigue<footnote ID="L43665e75-b23b-4801-9ac7-1d770e97ce7a">Grouped term includes asthenia.</footnote> </td> <td styleCode="Rrule" align="center">37</td> <td styleCode="Rrule" align="center">0.6</td> <td styleCode="Rrule" align="center">36</td> <td styleCode="Rrule" align="center">1.2</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5" align="left"> <content styleCode="bold">Infections and Infestations</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">COVID-19</td> <td styleCode="Rrule" align="center">33</td> <td styleCode="Rrule" align="center">0</td> <td styleCode="Rrule" align="center">29</td> <td styleCode="Rrule" align="center">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5" align="left"> <content styleCode="bold">Nervous System Disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Seizure<footnote ID="Lb105f824-2721-4c54-9496-645b42027d2c">Grouped term includes partial seizures, generalized tonic-clonic seizure, epilepsy, clonic convulsion, and simple partial seizures.</footnote> </td> <td styleCode="Rrule" align="center">16</td> <td styleCode="Rrule" align="center">4.2</td> <td styleCode="Rrule" align="center">15</td> <td styleCode="Rrule" align="center">3.7</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5" align="left"> <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Musculoskeletal pain<footnote ID="Le802ac44-b7d6-4c3d-bb1d-ca040cef7592">Grouped term includes arthralgia, back pain, non-cardiac chest pain, pain in extremity, myalgia, neck pain, musculoskeletal chest pain, arthritis, and musculoskeletal stiffness.</footnote> </td> <td styleCode="Rrule" align="center">26</td> <td styleCode="Rrule" align="center">0</td> <td styleCode="Rrule" align="center">25</td> <td styleCode="Rrule" align="center">1.8</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5" align="left"> <content styleCode="bold">Gastrointestinal Disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Diarrhea<footnote ID="L7c5307af-8ccb-479d-8e57-4dde55630d53">Grouped term includes feces soft and frequent bowel movements.</footnote> </td> <td styleCode="Rrule" align="center">25</td> <td styleCode="Rrule" align="center">0.6</td> <td styleCode="Rrule" align="center">17</td> <td styleCode="Rrule" align="center">0.6</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Constipation</td> <td styleCode="Rrule" align="center">13</td> <td styleCode="Rrule" align="center">0</td> <td styleCode="Rrule" align="center">12</td> <td styleCode="Rrule" align="center">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Abdominal pain<footnote ID="Ldc9730a6-d53f-4c9b-a901-11c48b3c9331">Grouped term includes abdominal pain upper, abdominal discomfort, abdominal pain lower, abdominal tenderness, and epigastric discomfort.</footnote> </td> <td styleCode="Rrule" align="center">13</td> <td styleCode="Rrule" align="center">0</td> <td styleCode="Rrule" align="center">12</td> <td styleCode="Rrule" align="center">0</td> </tr> <tr> <td styleCode="Lrule Rrule" align="left">Decreased appetite</td> <td styleCode="Rrule" align="center">9</td> <td styleCode="Rrule" align="center">0</td> <td styleCode="Rrule" align="center">3.7</td> <td styleCode="Rrule" align="center">0</td> </tr> </tbody> </table>
adverse reactions table
<table width="95%"> <caption>Table 4: Select Laboratory Abnormalities (≥5%) That Worsened from Baseline in Patients with Grade 2 IDH1/2 Mutant Glioma Who Received VORANIGO in the INDIGO Trial</caption> <colgroup> <col width="40%" align="left" valign="middle"/> <col width="15%" align="center" valign="middle"/> <col width="15%" align="center" valign="middle"/> <col width="15%" align="center" valign="middle"/> <col width="15%" align="center" valign="middle"/> </colgroup> <thead> <tr styleCode="Botrule First"> <th styleCode="Lrule Rrule" align="left"/> <th styleCode="Rrule" colspan="2" align="center">VORANIGO 40 mg daily N=167</th> <th styleCode="Rrule" colspan="2" align="center">Placebo N=163</th> </tr> <tr> <th styleCode="Lrule Rrule" align="left">Parameter</th> <th styleCode="Rrule" align="center">All Grades<footnote ID="L2446efbe-7dd7-437d-84a3-4106b1659759">Based on NCI CTCAE v5.0.</footnote> (%<footnote ID="L1d6efe83-1a67-4cef-baec-63407239be57">The denominator used to calculate percentages is N, the number of subjects in the Safety Analysis Set within each treatment group.</footnote>)</th> <th styleCode="Rrule" align="center">Grades<footnoteRef IDREF="L2446efbe-7dd7-437d-84a3-4106b1659759"/> 3 or 4 (%<footnoteRef IDREF="L1d6efe83-1a67-4cef-baec-63407239be57"/>)</th> <th styleCode="Rrule" align="center">All Grades<footnoteRef IDREF="L2446efbe-7dd7-437d-84a3-4106b1659759"/> (%<footnoteRef IDREF="L1d6efe83-1a67-4cef-baec-63407239be57"/>)</th> <th styleCode="Rrule" align="center">Grades<footnoteRef IDREF="L2446efbe-7dd7-437d-84a3-4106b1659759"/> 3 or 4 (%<footnoteRef IDREF="L1d6efe83-1a67-4cef-baec-63407239be57"/>)</th> </tr> </thead> <tfoot> <tr> <td colspan="5" align="left">Abbreviations: AST = Aspartate Aminotransferase; ALT = Alanine Aminotransferase; GGT = Gamma-Glutamyl Transferase; ALP = Alkaline Phosphatase</td> </tr> </tfoot> <tbody> <tr styleCode="Botrule First"> <td styleCode="Lrule Rrule" colspan="5" align="left"> <content styleCode="bold">Chemistry</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Increased ALT</td> <td styleCode="Rrule" align="center">59</td> <td styleCode="Rrule" align="center">10</td> <td styleCode="Rrule" align="center">25</td> <td styleCode="Rrule" align="center">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Increased AST</td> <td styleCode="Rrule" align="center">46</td> <td styleCode="Rrule" align="center">4.8</td> <td styleCode="Rrule" align="center">20</td> <td styleCode="Rrule" align="center">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Increased Creatinine</td> <td styleCode="Rrule" align="center">11</td> <td styleCode="Rrule" align="center">0.6</td> <td styleCode="Rrule" align="center">7</td> <td styleCode="Rrule" align="center">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Decreased Calcium</td> <td styleCode="Rrule" align="center">10</td> <td styleCode="Rrule" align="center">0</td> <td styleCode="Rrule" align="center">7</td> <td styleCode="Rrule" align="center">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Increased Glucose<footnote ID="L62127c5f-2b92-46eb-9eea-465528db777c">Includes adverse reaction term hyperglycemia.</footnote> </td> <td styleCode="Rrule" align="center">10</td> <td styleCode="Rrule" align="center">0</td> <td styleCode="Rrule" align="center">4.3</td> <td styleCode="Rrule" align="center">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Increased GGT</td> <td styleCode="Rrule" align="center">38</td> <td styleCode="Rrule" align="center">3</td> <td styleCode="Rrule" align="center">10</td> <td styleCode="Rrule" align="center">1.8</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Decreased Phosphate<footnote ID="L680fc6b0-c124-4e3d-aaa5-98fdaed2c12d">Includes adverse reaction terms hypophosphatemia and blood phosphorus decreased.</footnote> </td> <td styleCode="Rrule" align="center">8</td> <td styleCode="Rrule" align="center">0.6</td> <td styleCode="Rrule" align="center">4.9</td> <td styleCode="Rrule" align="center">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Increased Potassium</td> <td styleCode="Rrule" align="center">23</td> <td styleCode="Rrule" align="center">0.6</td> <td styleCode="Rrule" align="center">20</td> <td styleCode="Rrule" align="center">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Increased ALP</td> <td styleCode="Rrule" align="center">10</td> <td styleCode="Rrule" align="center">1.2</td> <td styleCode="Rrule" align="center">7</td> <td styleCode="Rrule" align="center">0.6</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="5" align="left"> <content styleCode="bold">Hematology</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Increased Hemoglobin</td> <td styleCode="Rrule" align="center">13</td> <td styleCode="Rrule" align="center">0</td> <td styleCode="Rrule" align="center">3.1</td> <td styleCode="Rrule" align="center">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Decreased Lymphocytes</td> <td styleCode="Rrule" align="center">11</td> <td styleCode="Rrule" align="center">1.8</td> <td styleCode="Rrule" align="center">8</td> <td styleCode="Rrule" align="center">0.6</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Decreased Leukocytes</td> <td styleCode="Rrule" align="center">13</td> <td styleCode="Rrule" align="center">0.6</td> <td styleCode="Rrule" align="center">12</td> <td styleCode="Rrule" align="center">0.6</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" align="left">Decreased Neutrophils</td> <td styleCode="Rrule" align="center">14</td> <td styleCode="Rrule" align="center">2.4</td> <td styleCode="Rrule" align="center">12</td> <td styleCode="Rrule" align="center">1.8</td> </tr> <tr> <td styleCode="Lrule Rrule" align="left">Decreased Platelets</td> <td styleCode="Rrule" align="center">12</td> <td styleCode="Rrule" align="center">0</td> <td styleCode="Rrule" align="center">4.3</td> <td styleCode="Rrule" align="center">0</td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.